| Calquence (acalabrutinib) / AstraZeneca |
NCT05024006: Public Health Emergency: SOLIDARITY TRIAL Philippines |
|
|
| Completed | N/A | 1314 | RoW | Remdesivir, Hydroxychloroquine, Lopinavir / Ritonavir, Interferon beta-1a, Acalabrutinib | University of the Philippines | Covid19 | 04/21 | 04/21 | | |
| Recruiting | N/A | 190 | Europe | acalabrutinib, Calquence | AstraZeneca, Yghea | Chronic Lymphocytic Leukemia | 02/30 | 02/30 | | |
REACH, NCT06170671: REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania |
|
|
| Recruiting | N/A | 250 | Europe | Non interventional study | AstraZeneca | Chronic Lymphocytic Leukemia | 09/28 | 09/28 | | |
NCT06561243: Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies |
|
|
| Active, not recruiting | N/A | 15000 | Europe | BTK inhibitor (Ibrutinib or Acalabrutinib) | University Hospital, Caen | Chronic B-cell Malignancies, BTK Inhibitors, Cardiovascular Diseases | 09/24 | 10/24 | | |
NCT04938141: MEOI and HRQoL in CLL Patients Treated With BTKis |
|
|
| Active, not recruiting | N/A | 23 | US | | AstraZeneca | Chronic Lymphocytic Leukemia | 09/24 | 09/24 | | |
NCT04872621: Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation |
|
|
| Active, not recruiting | N/A | 104 | Japan | | AstraZeneca | Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma) | 09/24 | 09/24 | | |
AQUALIS, NCT06548152: QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database |
|
|
| Not yet recruiting | N/A | 120 | NA | | AstraZeneca, Hospitalidee, Hospitalidee has been asserted to be a valid organization name by UHToulouse | Chronic Lymphocytic Leukemia | 12/25 | 12/25 | | |
CICERO, NCT05517265: Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation |
|
|
| Recruiting | N/A | 50 | Europe | Calquence | iOMEDICO AG, AstraZeneca | CLL | 10/25 | 10/25 | | |
| Active, not recruiting | N/A | 90 | RoW | | AstraZeneca | Chronic Lymphocytic Leukemia | 12/25 | 12/25 | | |
| Withdrawn | N/A | 160 | NA | Electrocardiogram, ECG, Echocardiogram, TTE, Cardiac magnetic resonance imaging, Cardiac MRI, Mobile cardiac telemetry, Mobile telemetry, Blood pressure monitoring, Home blood pressure monitoring, Blood draw | Dana-Farber Cancer Institute, AstraZeneca | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 01/26 | 01/28 | | |
EPIC, NCT05557695: Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom |
|
|
| Recruiting | N/A | 350 | Europe | Acalabrutinib, Calquence | AstraZeneca, UKCLL Forum | Chronic Lymphocytic Leukemia, CLL | 04/26 | 04/26 | | |
| Recruiting | N/A | 200 | Europe | | AstraZeneca | Chronic Lymphocytic Leukaemia (CLL) | 10/26 | 10/26 | | |
NCT05665374: Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study |
|
|
| Active, not recruiting | N/A | 67 | Japan | | AstraZeneca | Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma) | 05/26 | 05/26 | | |
NCT05950997: A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL |
|
|
| Recruiting | N/A | 89 | RoW | Acalabrutinib, Obinutuzumab | The First Affiliated Hospital with Nanjing Medical University, AstraZeneca | Chronic Lymphocytic Leukemia | 05/26 | 09/26 | | |
| Active, not recruiting | N/A | 350 | Europe | Non interventional study | AstraZeneca | Chronic Lymphocytic Leukemia | 11/26 | 11/26 | | |
| Active, not recruiting | N/A | 192 | Europe | | AstraZeneca | Chronic Lymphocytic Leukemia | 12/26 | 12/26 | | |
